ISCTM 2022: Scientific Posters Compilation September 19, 2022 Signant Health Posted in Scientific Advisory Share: LinkedInTweet Signant’s neuroscience team and CNS experts presented scientific posters at the 2022 Autumn Conference hosted by the International Society for CNS Clinical Trials and Methodology. The posters presented original research on a variety of topics related to the Positive and Negative Syndrome Scale (PANSS), including the potential impact of baseline PANSS symptom domain severity on interview duration and abnormal patterns of variability such as post-baseline 30/30 PANSS identical ratings. Separately, we examined whether a 10-item PANSS optimized for pediatric trials would perform similarly to the 30-item PANSS in an independent placebo-controlled multi-site trial. Other posters delved into research on the Mini-Mental State Exam (MMSE) for dementia, including the association between the MMSE interview duration and the presence of administration and/or scoring errors, and the impact of the number of per rater MMSE administrations on the probability of identifying an administration or scoring MMSE error. Browse through each poster below and meet our experts to learn how Signant has been optimizing CNS clinical research for over 20 years. The Impact of Baseline PANSS Factor Scores on the Incidence of Post-Baseline Identical Ratings Exploring the Impact of MMSE Assessment Duration on Scoring and Administration Errors Optimized 10 Item PANSS for Pediatric Trials: Comparison to 30 Item Version in a Multi-Site Trial for Adolescent Schizophrenia The Impact of Number of Prior In-Study MMSE Administrations on the Presence of MMSE Scoring or Administration Errors in Dementia Clinical Trials Does Baseline Symptom Domain Severity Predict Interview Duration in Acute Schizophrenia Clinical Trials? An Exploratory Retrospective Analysis Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics. Recent Posts Scientific Advisory 11 Perspectives on the Present and Future of Clinical Development Apr 13, 2023 Signant Health Learn more Clinical Supplies Consider Patients First in Direct-to-Patient Trial Designs Mar 31, 2023 James Stringer Learn more eCOA Clinical Viewpoints Episode 1 Recap – Optimizing Pediatric Trials to Generate High-Quality Data Feb 07, 2023 Signant Health Learn more eCOA Webinar Recap: Decentralized by Design-Optimizing Trials for Remote Conduct Feb 07, 2023 Signant Health Learn more eCOA Trial Optimization as the Focus for Decentralized Methods Dec 12, 2022 Signant Health Learn more
Signant’s neuroscience team and CNS experts presented scientific posters at the 2022 Autumn Conference hosted by the International Society for CNS Clinical Trials and Methodology. The posters presented original research on a variety of topics related to the Positive and Negative Syndrome Scale (PANSS), including the potential impact of baseline PANSS symptom domain severity on interview duration and abnormal patterns of variability such as post-baseline 30/30 PANSS identical ratings. Separately, we examined whether a 10-item PANSS optimized for pediatric trials would perform similarly to the 30-item PANSS in an independent placebo-controlled multi-site trial. Other posters delved into research on the Mini-Mental State Exam (MMSE) for dementia, including the association between the MMSE interview duration and the presence of administration and/or scoring errors, and the impact of the number of per rater MMSE administrations on the probability of identifying an administration or scoring MMSE error. Browse through each poster below and meet our experts to learn how Signant has been optimizing CNS clinical research for over 20 years. The Impact of Baseline PANSS Factor Scores on the Incidence of Post-Baseline Identical Ratings Exploring the Impact of MMSE Assessment Duration on Scoring and Administration Errors Optimized 10 Item PANSS for Pediatric Trials: Comparison to 30 Item Version in a Multi-Site Trial for Adolescent Schizophrenia The Impact of Number of Prior In-Study MMSE Administrations on the Presence of MMSE Scoring or Administration Errors in Dementia Clinical Trials Does Baseline Symptom Domain Severity Predict Interview Duration in Acute Schizophrenia Clinical Trials? An Exploratory Retrospective Analysis Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics.